Keywords: japan, tobacco, licenses, novel, hiv, integrase, inhibitor

Japan Tobacco licenses novel HIV integrase inhibitor to Gilead Sciences

Article | 28 March 2005

Print This

Gilead Sciences of the USA has licensed the commercialization and development rights to a novel HIV integrase inhibitor JTK-303 from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in